418 related articles for article (PubMed ID: 31473980)
1. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
Jenner P; Katzenschlager R
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
6. [Apomorphine in off state--clinical experience].
Rudzińska M; Szczudlik A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine in the treatment of Parkinson's disease.
Hagell P; Odin P
J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
10. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon.
Colosimo C; Merello M; Hughes AJ; Sieradzan K; Lees AJ
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):634-7. PubMed ID: 8648329
[TBL] [Abstract][Full Text] [Related]
11. A 10 year retrospective audit of long-term apomorphine use in Parkinson's disease.
Tyne HL; Parsons J; Sinnott A; Fox SH; Fletcher NA; Steiger MJ
J Neurol; 2004 Nov; 251(11):1370-4. PubMed ID: 15592733
[TBL] [Abstract][Full Text] [Related]
12. Continuous dopaminergic stimulation in Parkinson's disease.
Obeso JA; Luquin MR; Vaamonde J; Grandas F; Martinez Lage JM
Can J Neurol Sci; 1987 Aug; 14(3 Suppl):488-92. PubMed ID: 3676922
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
14. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
15. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
Stacy M; Silver D
Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
[TBL] [Abstract][Full Text] [Related]
16. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
17. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
18. [Use of apomorphine in Parkinson s disease].
Giménez-Roldán S; García- Muñozguren S
Rev Neurol; 2002 Oct 1-15; 35(7):668-74. PubMed ID: 12389155
[TBL] [Abstract][Full Text] [Related]
19. Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations.
Trenkwalder C; Chaudhuri KR; García Ruiz PJ; LeWitt P; Katzenschlager R; Sixel-Döring F; Henriksen T; Sesar Á; Poewe W; ; Baker M; Ceballos-Baumann A; Deuschl G; Drapier S; Ebersbach G; Evans A; Fernandez H; Isaacson S; van Laar T; Lees A; Lewis S; Martínez Castrillo JC; Martinez-Martin P; Odin P; O'Sullivan J; Tagaris G; Wenzel K
Parkinsonism Relat Disord; 2015 Sep; 21(9):1023-30. PubMed ID: 26189414
[TBL] [Abstract][Full Text] [Related]
20. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Obering CD; Chen JJ; Swope DM
Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]